Consistent differential effects of bupropion and mirtazapine in major depression
Journal of Affective Disorders · 2025-11 · 388 · 119551
DOI: 10.1016/j.jad.2025.119551 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025-11. Verfasst von Eric V Strobl. Beteiligte Einrichtung: Department of Biomedical Informatics, University of Pittsburgh, 5607 Baum Blvd, Room 523, Pittsburgh, PA 15206, United States of America; Department …. Hauptthemen laut MEDLINE: Bupropion, Major Depressive Disorder, Mianserin, Antidepressive Agents, Second-Generation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Patients with major depression exhibit heterogeneous symptom profiles and variable responses to antidepressants. Most clinical trials rely on aggregate outcomes such as total symptom severity or remission rates, which often obscure meaningful differences in treatment response. METHODS: We applied the Supervised Varimax (SV) algorithm to identify outcome dimensions that maximally differentiate antidepressants based on symptom-level effects. We analyzed all relevant levels of the STAR*D trial and validated findings in the independent CO-MED study. We assessed statistical significance using permutation testing with familywise error rate (FWER) correction. RESULTS: SV consistently identified interpretable and statistically significant differences between bupropion, mirtazapine, and other antidepressants. In STAR*D, bupropion monotherapy produced greater improvement in hypersomnia than venlafaxine in Levels 2 and 2 A (n=686, difference = 0.384, pFWER=0.007). Bupropion augmentation outperformed buspirone augmentation for increased weight, increased appetite, and fatigue in Level 2 (n=520, difference = -0.322, pFWER=0.005). Mirtazapine monotherapy outperformed nortriptyline for insomnia, decreased weight, and decreased appetite in Level 3 (n=214, difference = 0.401, pFWER=0.022), and venlafaxine with mirtazapine similarly outperformed tranylcypromine in Level 4 (n=102, difference = -0.722, pFWER=0.004). In CO-MED, escitalopram with bupropion and venlafaxine with mirtazapine demonstrated complementary symptom-specific benefits (n=640, difference = -0.302, pFWER=0.022). CONCLUSION: Bupropion is most effective for hypersomnia, increased weight, increased appetite, or fatigue, while mirtazapine is preferable for insomnia, decreased weight, or decreased appetite. SV enables statistically rigorous, symptom-level differentiation using only treatment assignment, offering a scalable and clinically aligned framework for guiding antidepressant selection from individual clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Informatics, University of Pittsburgh, 5607 Baum Blvd, Room 523, Pittsburgh, PA 15206, United States of America; Department of Psychiatry, University of Pittsburgh, 3811 O'Hara St, Pittsburgh, P…
Zitieren
APA
Strobl, E. V. (2025). Consistent differential effects of bupropion and mirtazapine in major depression. Journal of Affective Disorders, 388, 119551. https://doi.org/10.1016/j.jad.2025.119551
Vancouver
Strobl EV. Consistent differential effects of bupropion and mirtazapine in major depression. Journal of Affective Disorders. 2025;388:119551. doi:10.1016/j.jad.2025.119551
BibTeX
@article{Strobl2025,
author = {Strobl, Eric V},
title = {Consistent differential effects of bupropion and mirtazapine in major depression},
journal = {Journal of Affective Disorders},
year = {2025},
volume = {388},
pages = {119551},
doi = {10.1016/j.jad.2025.119551}
}
EUVIMED